BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16990760)

  • 21. The evaluation of red blood cell folate and methotrexate levels during protocol M in childhood acute lymphoblastic leukemia.
    Oosterom N; Fiocco M; Kloos RQH; van der Sluis IM; Pieters R; van Zelst BD; Smith DEC; van den Heuvel-Eibrink MM; de Jonge R; Heil SG
    BMC Cancer; 2020 Sep; 20(1):940. PubMed ID: 32998716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China.
    Xu W; Tang Y; Song H; Shi S; Yang S
    J Pediatr Hematol Oncol; 2007 Oct; 29(10):688-93. PubMed ID: 17921849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Blood concentration monitoring during high-dose methotrexate treatment].
    Jiao L; Zhou DB; Wang SJ; Zhang W; Duan MH; Li J; Han B; Xu Y; Zhao YQ; Shen T; Wang Q; Ye M
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):564-6. PubMed ID: 19968071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Methotrexate-induced interstitial pneumonitis in a child with acute lymphoblastic leukemia].
    Tatsumoto C; Kawakami K; Nagayama J; Kawano H
    Rinsho Ketsueki; 2004 Oct; 45(10):1100-4. PubMed ID: 15553044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
    Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
    Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Assessment of elimination and tolerance of high dose of methotrexate (3 g/m2) in children with standard-risk acute lymphoblastic leukemia].
    Cwliklińska M; Balwierz W; Nowak J; Stanuch H
    Przegl Lek; 2006; 63(1):15-20. PubMed ID: 16892893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leucovorin and maximum tolerated dose toxicity of methotrexate in rats.
    Fuskevåg OM; Kristiansen C; Lindal S; Aarbakke J
    Pediatr Hematol Oncol; 2000 Dec; 17(8):651-8. PubMed ID: 11127396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia.
    Dördelmann M; Reiter A; Zimmermann M; Fengler R; Henze G; Riehm H; Schrappe M
    J Pediatr Hematol Oncol; 1998; 20(5):444-50. PubMed ID: 9787317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate].
    Etienne MC; Thyss A; Bertrand Y; Rubie H; Milano G
    Bull Cancer; 1993 Apr; 80(4):357-63. PubMed ID: 8173189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia.
    Shuper A; Stark B; Kornreich L; Cohen IJ; Avrahami G; Yaniv I
    Isr Med Assoc J; 2002 Nov; 4(11):1050-3. PubMed ID: 12489505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate.
    Refsum H; Wesenberg F; Ueland PM
    Cancer Res; 1991 Feb; 51(3):828-35. PubMed ID: 1988122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Pediatric Leukemia/Lymphoma Study Group experience].
    Derwich K; Wachowiaki J; Kaczmarek-Kanoldi M; Balcerska A; Balwierz W; Chybicka A; Kowalczyk JR; Matysiak M; Jackowska T; Sońta-Jakimczyk D; Wysocki M; Chełmecka-Hanuszewicz L; Cwiklińska M; Kołtan A; Malinowska I; Odój T; Płoszyńska A; Steczowicz M; Wojciechowska V; Wójtowicz A;
    Przegl Lek; 2006; 63(1):7-10. PubMed ID: 16892891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Investigation on individualized adjustment of target range of high-dose methotrexate].
    Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
    Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
    Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Toxicosis of high-dose methotrexate (HD-MTX) for osteosarcoma, cured with treatment by leucovorin (LV) rescue and hemoperfusion--a case report].
    Kobayashi H; Morita T; Hirata Y; Kato T; Okada Y; Sato T
    Gan To Kagaku Ryoho; 2000 Mar; 27(3):475-8. PubMed ID: 10740644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Kinoshita A; Kurosawa Y; Kondoh K; Suzuki T; Manabe A; Inukai T; Sugita K; Nakazawa S
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):256-60. PubMed ID: 12655445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Studies of methotrexate pharmacokinetics in children with neoplasms of the hematopoietic system after administration of different doses of the drug].
    Wysocki M; Krzyzanowski M; Ozyński T; Pilecki O; Balcar-Boroń A; Szadujkis-Szadurski L
    Acta Haematol Pol; 1992; 23(3):179-83. PubMed ID: 1492542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value?
    Martelli N; Mathieu O; Margueritte G; Bozonnat MC; Daurès JP; Bressolle F; Hillaire-Buys D; Peyrière H
    J Clin Pharm Ther; 2011 Apr; 36(2):237-45. PubMed ID: 21366654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy, side effects and blood concentration monitoring of high-dose methotrexate in treatment of 180 children with acute lymphoblastic leukemia].
    Wang H; Chi ZF; Li S; Wang XL; Hao LC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):949-52. PubMed ID: 21867621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Schmiegelow K; Bretton-Meyer U
    Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.